Aytu Biopharma (AYTU) Total Current Liabilities (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Total Current Liabilities data on file, last reported at $60.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 15.18% year-over-year to $60.0 million in Q1 2026; TTM through Mar 2026 was $60.0 million, a 15.18% decrease from a year earlier, with the FY2025 full-year figure at $63.1 million, up 1.34% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $60.0 million, down from $65.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for AYTU reached as high as $85.4 million in Q1 2023 and fell as low as $60.0 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $68.6 million across 5 years, with a median of $65.6 million in 2025.
• Across the five-year window, Total Current Liabilities slumped 41.12% in 2022 and grew 7.74% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $67.1 million in 2022, then dropped by 4.41% to $64.2 million in 2023, then fell by 0.22% to $64.0 million in 2024, then advanced by 2.37% to $65.6 million in 2025, then decreased by 8.53% to $60.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $60.0 million in Q1 2026, $65.6 million in Q4 2025, and $66.0 million in Q3 2025.